QC
ALNY icon

Quent Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quent Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Sell
50
-17
-25% -$5.13K ﹤0.01% 1143
2026
Q1 		$22.2K Sell
67
-27
-29% -$9.19K ﹤0.01% 959
2025
Q4 		$37.4K Buy
94
+9
+11% +$3.98K ﹤0.01% 829
2025
Q3 		$38.8K Buy
+85
New +$34.6K ﹤0.01% 672
2025
Q2 		– Sell
-17
Closed -$4.59K – 324
2025
Q1 		$4.59K Hold
17
– – ﹤0.01% 1031
2024
Q4 		$4K Buy
17
+1
+6% +$263 ﹤0.01% 1083
2024
Q3 		$4.4K Hold
16
– – ﹤0.01% 1123
2024
Q2 		$3.89K Sell
16
-155
-91% -$24.5K ﹤0.01% 1124
2024
Q1 		$25.6K Sell
171
-2
-1% -$334 ﹤0.01% 818
2023
Q4 		$33.1K Buy
173
+123
+246% +$21K ﹤0.01% 720
2023
Q3 		$8.86K Sell
50
-8
-14% -$1.53K ﹤0.01% 956
2023
Q2 		$11K Hold
58
– – ﹤0.01% 916
2023
Q1 		$11.6K Buy
58
+50
+625% +$10.5K ﹤0.01% 892
2022
Q4 		$1.9K Buy
+8
New +$1.71K ﹤0.01% 1159

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quent Capital's ALNY Position: Q2 2026 in Review

Quent Capital reduced its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q2 2026, selling an estimated $5.13K and leaving 50 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1143.

Quent Capital first reported a position in ALNY in Q4 2022 and has held it in 14 quarters since. The position peaked at $38.8K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Quent Capital held 50 shares of Alnylam Pharmaceuticals worth $15.1K as of Q2 2026.
  • Quent Capital sold 17 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.13K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1143 holding.
  • Quent Capital first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Quent Capital's Alnylam Pharmaceuticals position peaked at $38.8K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.